Search

everythinglearnresearchcommunity

for

Search:↓

Researchers created a mouse with the same mutation as humans with trichothiodystrophy, showing similar symptoms and confirming the condition is due to defects in DNA repair and gene activity.

New therapies are being developed that target integrin pathways to treat various diseases.

Congenital triangular alopecia and vitiligo can occur together, but treatment for one may not affect the other.

Tislelizumab can cause cutaneous lupus erythematosus.

Transit-amplifying cells are crucial for tissue repair and can contribute to cancer when they malfunction.

CTIP2 may help in skin development and maintenance.

Trichoscopy effectively diagnoses temporal triangular alopecia in children.

Matriptase imbalance contributes to cancer development and spread.

Autoimmune reactions may cause both alopecia areata and HAM.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

ILC1-like cells can cause alopecia areata by affecting hair follicles.

Overexpressing IGF-1 in mice leads to skin abnormalities and tumors.

Inhibiting TYK2 can restore hair growth in alopecia areata.

Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.

Two sisters had a rare hair condition without other usual symptoms.

Mast cells and the CB1 receptor may be key in causing IgA vasculitis.

The study found two new mutations in a Chinese patient with severe biotinidase deficiency.

TYK2 inhibitors show promise for treating cancer and autoimmune disorders.

Topical tofacitinib shows promise as a future treatment for alopecia areata.

The sensor accurately measures thallium ions in solutions with high selectivity.

CRAC channels are crucial for the development and function of specialized immune cells, preventing severe inflammation and autoimmune diseases.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Innate lymphoid cells type 1 may contribute to alopecia areata by damaging hair follicles.

Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.

LTBP1 is a key regulator in diseases and a potential target for new treatments.

Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.

Mitf plays a key role in melanoma progression and is linked to disease stage.

TNF-a may not be as involved in certain types of hair loss as previously thought.